Clinical Study Results
Overall, during the study, there were more episodes that were adjudicated as a
definite DKA in participants who took either dose of dapagliflozin.
Participants with episodes of adjudicated DKA during the study
5 mg of 10 mg of
dapagliflozin dapagliflozin Placebo
with insulin with insulin with insulin
(out of 271 (out of 270 (out of 272
participants) participants) participants)
Participants with an event
4.1% (11) 3.7% (10) 0.4% (1)
adjudicated as definite DKA
Participants with an event
3.0% (8) 1.5% (4) 0.7% (2)
adjudicated as possible DKA
Participants with an event
3.7% (10) 3.7% (10) 3.3% (9)
adjudicated as unlikely to be DKA
How has this study helped patients and researchers?
These results helped researchers learn more about how dapagliflozin affects
HbA1c levels in people with type 1 diabetes.
Researchers look at the results of many studies to decide which treatments work
best and are safest. This summary shows only the main results from this one
study. Other studies may provide new information or different results.
Further clinical studies with dapagliflozin and insulin taken together are planned.
11